An internal standard for the quantification of rivaroxaban
Related Products
Unlabeled Version(s)
16043Rivaroxaban
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Rivaroxaban-d4

Item No. 22563

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl-2,3,5,6-d4]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide
CAS Number
1132681-38-9
Molecular Formula
C19H14ClD4N3O5S
Formula Weight
439.9
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble
SMILES
O=C1N(C2=C([2H])C([2H])=C(N3C[C@H](CNC(C4=CC=C(Cl)S4)=O)OC3=O)C([2H])=C2[2H])CCOC1
InChi Code
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1/i1D,2D,3D,4D
InChi Key
KGFYHTZWPPHNLQ-UJCPGTITSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $203

    Add

    1 mg

    $336

    Add
    Product Description

    Rivaroxaban-d4 is intended for use as an internal standard for the quantification of rivaroxaban (Item No. 16043) by GC- or LC-MS. Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade.1 It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time. Formulations containing rivaroxaban have been used as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Turpie, A.G.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 27(6), 1238-1247 (2007).

    2. Babilonia, K., and Trujillo, T. The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb. J. 12:8, (2014).

    3. Turpie, A.G.G. Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther. Clin. Risk Manag. 10, 197-205 (2014).